Actinogen is the only ASX-listed developer of an Alzheimer’s disease treatment. The portents are positive, with the study in ...

Early discontinuation of intravenous antibiotics regardless of neutrophil recovery reduced unnecessary antibiotic exposure without indications of compromised safety. Although the study was not powered ...

Mesoblast offers asymmetric risk-reward with Ryoncil's rapid pediatric SR-aGvHD launch and multiple late-stage pipeline catalysts. Learn why MESO stock is a hold.

FDA has accepted and granted Priority Review to the biologics license application for ifinatamab deruxtecan in adults with ...

Since the FDA began publishing its rejections of drug approval filings in July last year, companies have become more ...